In increasing numbers, Americans will seek to satisfy nicotine addictions through the use of novel nicotine-delivery products devoid of several of the poisons that make cigarettes so deadly.
In the vanguard are tobacco industry devices that heat tobacco derivatives rather than burn tobacco, and pharmaceutical industry nicotine-replacement products, with nicotine gum and the patch now available over the counter.
Ostensibly, these 2 industries have diametrically opposed objectives, the tobacco industry striving to sustain nicotine addictions, the pharmaceutical industry to end them.
However, a series of technological, economic, political, regulatory, and social developments augurs a strange-bedfellows competition in which these industries will vie for shares of a new multibillion dollar long-term nicotine-maintenance market.
Regulatory options range from encouraging competition to banning all nicotine-delivery devices.
A more realistic approach discourages use of the most dangerous products, while making less hazardous products readily available to adults.
Mots-clés Pascal : Tabagisme, Epidémiologie, Etude comparative, Nicotine, Industrie pharmaceutique, Filtre cigarette, Facteur efficacité, Politique commerciale, Homme, Toxicologie, Education santé, Vasodilatateur
Mots-clés Pascal anglais : Tobacco smoking, Epidemiology, Comparative study, Nicotine, Pharmaceutical industry, Cigarette filter, Effectiveness factor, Marketing policy, Human, Toxicology, Health education, Vasodilator agent
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0515090
Code Inist : 002B03E. Création : 13/02/1998.